High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo

Tacke, Frank; Wüstefeld, Torsten; Horn, Rüdiger; Luedde, Tom; Rao, Annavarapu Srinivas; Manns, Michael P.; Trautwein, Christian; Brabant, Georg

doi:10.1016/j.jhep.2004.12.024

Cited by 117 publications

(124 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adiponectin is positively correlated with a AST, b ALT, c CRP, e alkaline phosphatase, f GGT and inversely correlated with serum albumin (d) complications of cirrhosis such as ascites and development of esophageal varices did not affect the levels of adiponectin. Similar results were reported by Tacke et al [28].…”

Section: Discussionsupporting

confidence: 92%

“…2 Adiponectin value in different grades of cirrhosis adiponectin paradoxically increased with aminotransferase activities as markers of liver cell injury. Similar results were reported by Tacke et al [28]. Jonsson [10] related the increment of adiponectin in chronic liver disease to increased inflammation and increased hepatic adiponectin immunoreactivity.…”

Section: Discussionsupporting

confidence: 87%

“…This raises the suggestion that adiponectin might be elevated in cholestasis due to decreased biliary excretion. Although kidneys have been proposed to play a role in adiponectin biodegradation and/or elimination [33,34], Tacke et al [28] showed very high adiponectin levels in human bile in biliary obstruction suggesting that biliary excretion contributes to its clearance. Floreani et al [35] observed that the high levels of adiponectin in patients with primary biliary cirrhosis is correlated with GGT as observed in the current study.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Study of adiponectin in chronic liver disease and cholestasis

et al. 2010

View full text Add to dashboard Cite

Purpose Adiponectin is an adipocytokine suggested to have a hepatoprotective effect. To date, little information is available in the literature regarding changes in serum adiponectin levels in cirrhosis and cholestasis and the associated metabolic disturbances. In order to elucidate the role of adiponectin in chronic liver disease our aim was to determine serum adiponectin in patients with different grades of cirrhosis and cholestasis and to correlate it with markers of liver injury, inflammation and cholestasis. We also aimed to correlate adiponectin with markers of metabolic syndrome such as body mass index and insulin resistance. Methods Forty patients with cirrhosis; 30 patients with cirrhosis and cholestasis; and 20 matched controls were studied. They were subjected to clinical assessment, laboratory investigations: serum bilirubin, ALT, AST, alkaline phosphatase, GGT, albumin, C-reactive protein, prothrombin activity, fasting blood sugar, insulin. HOMA index was calculated. Abdominal ultrasonography and upper GI endoscopy were performed. Results Adiponectin was elevated in patients with cirrhosis and cirrhosis/cholestasis and was significantly higher in Child A and B. Adiponectin showed correlation with liver cell injury, marker of inflammation, synthetic liver function and markers of cholestasis. Adiponectin did not correlate with complications of cirrhosis as ascites and esophageal varices nor did it correlate with BMI or HOMA. Conclusions Adiponectin is elevated in cirrhosis and shows correlation with degree of hepatocellular injury and cholestasis. Finally, adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism but exclusively with reduced liver function.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Study of adiponectin in chronic liver disease and cholestasis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Here we show that in the presence of adiponectin, TIMP-1 levels are unexpectedly elevated but that this in fact may assist in limiting fibrosis by reducing HSC invasion and migration through the extracellular matrix. Our findings may have relevance for all forms of advanced liver fibrosis as several studies now indicate that irrespective of etiology, adiponectin (19,(41)(42)(43) and TIMP-1 levels are elevated (8,9,20). If indeed adiponectin is causally associated with increasing TIMP-1 in these patients, then we would expect that those with low serum adiponectin and advanced fibrosis would have lower levels of TIMP-1 protein.…”

Section: Discussionmentioning

confidence: 55%

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

Ramezani-Moghadam

Wang

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Adiponectin has been shown to limit liver fibrosis, but the molecular mechanisms remain unknown. Results: In vitro and in vivo adiponectin increases TIMP-1 secretion, which binds to the CD63/␤1-integrin complex to decrease FAK activity and stellate cell migration. Conclusion: Adiponectin-promoted TIMP-1 plays an important role in limiting liver fibrosis. Significance: Targeting adiponectin signaling could be a useful way to limit liver fibrosis.

show abstract

“…Consistently, serum adiponectin levels tend to be lower in patients with elevated serum alanine aminotransferase (ALT) values and those with fibrosis [23,26,27]. Paradoxically, serum adiponectin level seemed higher in patients with impaired liver function such as those with advanced fibrosis or cirrhosis, possibly because of decreased hepatic extraction of adiponectin [28][29][30].…”

Section: Introductionmentioning

confidence: 99%

High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection

et al. 2008

View full text Add to dashboard Cite

Purpose Adiponectin possesses anti-inflammatory and insulin-sensitizing properties. Little is known about the role of adiponectin in hepatitis B-related liver disease.Methods Serum adiponectin and hepatitis B viral factors were cross-sectionally assayed in 280 patients with chronic hepatitis B virus (HBV) infection including 120 patients with chronic HBV infection, 40 patients with cirrhosis, and 120 patients with hepatocellular carcinoma (HCC); 116 healthy adults were used as controls. The dynamics of serum adiponectin level was also studied longitudinally in 25 patients with hepatitis B e antigen (HBeAg) seroconversion (SC). Results We found that serum adiponectin level in patients with chronic HBV infection was similar to that in healthy controls and was significantly lower than patients with cirrhosis and HCC. In univariate analysis, high serum adiponectin level significantly correlated with the presence of HBV-related cirrhosis or HCC, abnormal serum ALT level, and HBV genotype C. Multivariate analysis revealed that high serum adiponectin level significantly correlated with the development of HCC. Serum adiponectin levels remained stationary in patients experiencing HBeAg SC. Conclusions Our findings suggest that HBV infection itself does not affect adiponectin levels. Serum adiponectin level correlates with the progression of HBV-related liver diseases but not with the development of HBeAg SC.

show abstract

High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo

Cited by 117 publications

References 44 publications

Study of adiponectin in chronic liver disease and cholestasis

Study of adiponectin in chronic liver disease and cholestasis

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection

Contact Info

Product

Resources

About